Federated Hermes Inc. Trims Stock Position in Sanofi (NASDAQ:SNY)

Federated Hermes Inc. decreased its position in Sanofi (NASDAQ:SNY) by 25.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,491,314 shares of the company’s stock after selling 834,724 shares during the period. Federated Hermes Inc. owned about 0.10% of Sanofi worth $120,156,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in shares of Sanofi during the 4th quarter worth $135,933,000. Boston Partners raised its position in shares of Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after purchasing an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC lifted its position in shares of Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after acquiring an additional 1,705,148 shares in the last quarter. DAVENPORT & Co LLC lifted its holdings in Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its stake in shares of Sanofi by 36.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock valued at $93,774,000 after buying an additional 514,542 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Trading Down 4.8 %

SNY opened at $51.98 on Friday. The firm’s 50 day moving average is $55.37 and its 200-day moving average is $52.68. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $131.92 billion, a P/E ratio of 20.88, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several recent analyst reports. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.